Novavax, Inc.

NASDAQ:NVAX

Biotechnology

Healthcare
$7.96 -1.84%

-$0.18 today

Market cap
$1.31B
Beta
2.41
P/E (TTM)
-17.3
EPS (TTM)
-$0.54
52W Low $6.13High $11.97

Volume 4.24M

Average 4.58M

NVAX Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Novavax, Inc.NASDAQ: NVAX

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to 78.0%

Gross margin was 78.0% in Q1 FY2026, down 19.9 pp from a year earlier. On a trailing-twelve-month basis it was 84.6%, down 2.8 pp year over year. Over 3 fiscal years it widened by 50.1 pp.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
78.0%-4.9 pp QoQ
Last fiscal yearDec 2025
93.7%+23.4 pp YoY
LTMMar 2026
84.6%-2.8 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-19.9 pp——
1 year+23.4 pp——
3 years+50.1 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
93.7%
Year-over-year change
+23.4pp

Gross Margin vs competitors

How NVAX compares with its peers on the latest reported figures

  • NVAX's LTM Mar 2026 gross margin of 84.6% is the 3rd highest of the 7 companies compared; the peer median is 57.6%.
  • Its year-over-year change of -2.8 pp is the 4th highest of 7, against a peer median of -4.4 pp.
  • Over three fiscal years its change of +50.1 pp compares with a peer median of -2.3 pp.
NVAX Competitors Peer median
Gross Margin for NVAX and competitors
Company Period LTM level YoY 3-year change
INOInovio Pharmaceuticals, Inc.FY2025100.0% +0.0 pp+0.0 pp
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 202691.2% -8.8 pp-4.5 pp
NVAXNovavax, Inc.LTM Mar 202684.6% -2.8 pp+50.1 pp
BNTXBioNTech SELTM Jun 202670.8% -8.9 pp-5.1 pp
EBSEmergent BioSolutions Inc.LTM Mar 202644.4% +8.0 pp+4.9 pp
VALNValneva SELTM Mar 202629.5% -17.1 pp+28.5 pp
MRNAModerna, Inc.LTM Sep 202628.0% +16.1 pp-16.0 pp
PCVXVaxcyte, Inc.FY2025— ——
Peer median (excluding NVAX) 57.6%-4.4 pp-2.3 pp

Competitors are the stored peer set for NVAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue197.58M1.6B556.38M682.16M1.12B
Cost of Revenue0902.64M343.77M202.74M71.14M
Gross Profit197.58M696.31M212.61M479.42M1.05B
Gross Margin100.0%43.5%38.2%70.3%93.7%
Research & Development2.53B1.24B737.5M391.17M336.82M
Selling, General & Admin298.36M488.69M468.95M337.19M150.35M
Operating Expenses1.88B1.34B779.13M728.35M489.07M
Depreciation & Amortization12.66M29.05M41.23M48.5M27.61M
EBITDA(1.68B)(604.71M)(487.39M)(108.04M)492.33M
EBITDA Margin-850.7%-37.8%-87.6%-15.8%43.8%
Operating Income(1.69B)(644.74M)(566.51M)(248.93M)563.27M
Operating Margin-853.6%-40.3%-101.8%-36.5%50.1%
Interest Income00000
Interest Expense21.13M19.88M14.42M20.08M22.55M
Other Income / Expenses(27.96M)(8.91M)23.48M72.32M(121.1M)
Income Before Tax(1.71B)(653.65M)(543.03M)(176.62M)442.17M
Pre-Tax Margin-867.8%-40.9%-97.6%-25.9%39.4%
Income Tax Expense29.22M4.29M2.03M10.88M1.87M
Net Income(1.74B)(657.94M)(545.06M)(187.5M)440.3M
Net Margin-882.5%-41.1%-98.0%-27.5%39.2%
EPS (Basic)(23.44)(8.42)(5.41)(1.23)2.72
EPS (Diluted)(23.44)(8.42)(5.41)(1.23)2.54
Weighted Avg Shares74.4M78.18M100.77M152.19M161.99M
Weighted Avg Shares (Diluted)74.4M78.18M100.77M152.19M173.1M

Novavax, Inc.

NASDAQ:NVAX

Intrinsic Alpha fair value

Locked

Current Price

$7.96

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.